Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response.

Abstract

Pathologic complete response (pCR) was noted to be prognostic in all but hormone receptor-positive (HR) breast cancer cases even when HER2 is overexpressed. Evocative data suggest that HER2-positive breast cancer patients are a heterogeneous population and a subset of HER2-positive and HR-positive tumors biologically behave more like HER2-negative… (More)
DOI: 10.1016/j.breast.2013.12.005

Topics

  • Presentations referencing similar topics